Article
The Use of Biosimilars in Oncology
Host Dr. John Sweetenham, associate director of Clinical Affairs at the UT Southwestern Harold C. Simmons Comprehensive Cancer Center, and Dr. Zeina Nahleh, breast cancer medical oncologist and regional chair of the Cleveland Clinic Florida Cancer Institute, discuss the new ASCO Expert Panel report on the use of biosimilars in oncology, and their potential as an affordable, effective alternative for cancer care.
Related Topics
You May Also Like
Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
Article